APM
MDGL icon

Avidity Partners Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Avidity Partners Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,000
Closed -$5.75M – 54
2025
Q2 		$5.75M Buy
+19,000
New +$5.66M 1.15% 32
2023
Q1 		– Sell
-430,000
Closed -$125M – 90
2022
Q4 		$125M Buy
+430,000
New +$42.1M 2.7% 12
2020
Q1 		– Sell
-15,000
Closed -$1.37M – 59
2019
Q4 		$1.37M Buy
+15,000
New +$1.45M 0.86% 29

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Avidity Partners Management's MDGL Position: Q3 2025 in Review

Avidity Partners Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 19,000 shares — an estimated $5.75M sold.

Avidity Partners Management first reported a position in MDGL in Q4 2019 and held it in 3 quarters. The position peaked at $125M in Q4 2022. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Avidity Partners Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Avidity Partners Management sold 19,000 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $5.75M.
  • Avidity Partners Management first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • Avidity Partners Management's Madrigal Pharmaceuticals position peaked at $125M in Q4 2022.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.